The Prognostic Signature of Head and Neck Squamous Cell Carcinoma Constructed by Immune-Related RNA-Binding Proteins

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Apr 22

PMID 35449571

Authors

Ruijie Ming

Xiangrui Li

Enhao Wang

JiaHui Wei

Bo Liu

Peng Zhou

Wenting Yu

Shimin Zong

Hongjun Xiao

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to construct a prognostic signature consisting of immune-related RNA-binding proteins (RBPs) to predict the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) effectively.

Methods: The transcriptome and clinical data of HNSCC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. First, we ascertained the immunological differences in HNSCC, through single-sample gene set enrichment analysis, stromal and immune cells in malignant tumor tissues using expression data (ESTIMATE), and cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) deconvolution algorithm. Then we used univariate proportional hazards (Cox) regression analysis and least absolute shrinkage and selection operator (LASSO) Cox regression analysis to screen immune-related RBPs and acquire the risk score of each sample. Subsequently, we further investigated the difference in prognosis, immune status, and tumor mutation burden in high- and low-risk groups. Finally, the efficacy of immunotherapy was measured by the tumor immune dysfunction and exclusion (TIDE) score.

Results: We derived 15 immune-related RBPs, including FRMD4A, ASNS, RAB11FIP1, FAM120C, CFLAR, CTTN, PLEKHO1, SELENBP1, CHCHD2, NPM3, ATP2A3, CFDP1, IGF2BP2, NQO1, and DENND2D. There were significant differences in the prognoses of patients in the high- and low-risk groups in the training set ( < 0.001) and the validation set ( < 0.01). Furthermore, there were statistical differences between the high-risk group and low-risk group in immune cell infiltration and pathway and tumor mutation load ( < 0.001). In the end, we found that patients in the low-risk group were more sensitive to immunotherapy ( < 0.001), and then we screened 14 small-molecule chemotherapeutics with higher sensitivity to the high-risk group ( < 0.001).

Conclusion: The study constructed a prognostic signature of HNSCC, which might guide clinical immunotherapy in the future.

Citing Articles

T cell proliferation-related subtypes, prognosis model and characterization of tumor microenvironment in head and neck squamous cell carcinoma.

Jiang W, Yang Q, Yang X, Gan R, Hua H, Ding Z Heliyon. 2024; 10(14):e34221.

PMID: 39082023 PMC: 11284379. DOI: 10.1016/j.heliyon.2024.e34221.

Identification of a new anoikis-related gene signature for prognostic significance in head and neck squamous carcinomas.

Wei Z, Zhou C, Shen Y, Deng H, Shen Z Medicine (Baltimore). 2023; 102(36):e34790.

PMID: 37682196 PMC: 10489427. DOI: 10.1097/MD.0000000000034790.

Protein-RNA interactions: from mass spectrometry to drug discovery.

Steinmetz B, Smok I, Bikaki M, Leitner A Essays Biochem. 2023; 67(2):175-186.

PMID: 36866608 PMC: 10070478. DOI: 10.1042/EBC20220177.

Transcriptomic signature associated with RNA-binding proteins for survival stratification of laryngeal cancer.

Shen Y, Chen H, Huang Q, Du H, Zhou L Aging (Albany NY). 2022; 14(16):6605-6625.

PMID: 35985767 PMC: 9467394. DOI: 10.18632/aging.204234.

References

Baltz A, Munschauer M, Schwanhausser B, Vasile A, Murakawa Y, Schueler M . The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol Cell. 2012; 46(5):674-90. DOI: 10.1016/j.molcel.2012.05.021. View

Brannan K, Jin W, Huelga S, Banks C, Gilmore J, Florens L . SONAR Discovers RNA-Binding Proteins from Analysis of Large-Scale Protein-Protein Interactomes. Mol Cell. 2016; 64(2):282-293. PMC: 5074894. DOI: 10.1016/j.molcel.2016.09.003. View

Cohen E, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn M . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2018; 393(10167):156-167. DOI: 10.1016/S0140-6736(18)31999-8. View

Chou C, Chang C, Lu H, Hsin M, Chen M, Huang H . IGF2BP2 Polymorphisms Are Associated with Clinical Characteristics and Development of Oral Cancer. Int J Mol Sci. 2020; 21(16). PMC: 7460642. DOI: 10.3390/ijms21165662. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Ling B, Zheng H, Fu G, Yuan J, Shi T, Chen S . Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D. Lung Cancer. 2012; 79(2):104-10. DOI: 10.1016/j.lungcan.2012.10.012. View

Mounir M, Lucchetta M, C Silva T, Olsen C, Bontempi G, Chen X . New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput Biol. 2019; 15(3):e1006701. PMC: 6420023. DOI: 10.1371/journal.pcbi.1006701. View

Norouzian M, Mehdipour F, Balouchi Anaraki S, Ashraf M, Khademi B, Ghaderi A . Atypical Memory and Regulatory B Cell Subsets in Tumor Draining Lymph Nodes of Head and Neck Squamous Cell Carcinoma Correlate with Good Prognostic Factors. Head Neck Pathol. 2019; 14(3):645-656. PMC: 7413970. DOI: 10.1007/s12105-019-01095-1. View

Castello A, Fischer B, Frese C, Horos R, Alleaume A, Foehr S . Comprehensive Identification of RNA-Binding Domains in Human Cells. Mol Cell. 2016; 63(4):696-710. PMC: 5003815. DOI: 10.1016/j.molcel.2016.06.029. View

10.

Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A . Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. Ann Oncol. 2018; 29(12):2313-2327. DOI: 10.1093/annonc/mdy452. View

11.

Veeramachaneni R, Walker T, Revil T, de Weck A, Badescu D, OSullivan J . Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy. Sci Rep. 2019; 9(1):11992. PMC: 6700135. DOI: 10.1038/s41598-019-48229-7. View

12.

Zhong J, Jermusyk A, Wu L, Hoskins J, Collins I, Mocci E . A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. J Natl Cancer Inst. 2020; 112(10):1003-1012. PMC: 7566474. DOI: 10.1093/jnci/djz246. View

13.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

14.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

15.

Trendel J, Schwarzl T, Horos R, Prakash A, Bateman A, Hentze M . The Human RNA-Binding Proteome and Its Dynamics during Translational Arrest. Cell. 2018; 176(1-2):391-403.e19. DOI: 10.1016/j.cell.2018.11.004. View

16.

New J, Arnold L, Ananth M, Alvi S, Thornton M, Werner L . Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res. 2017; 77(23):6679-6691. PMC: 5712244. DOI: 10.1158/0008-5472.CAN-17-1077. View

17.

Li H, Ning S, Ghandi M, Kryukov G, Gopal S, Deik A . The landscape of cancer cell line metabolism. Nat Med. 2019; 25(5):850-860. PMC: 6629041. DOI: 10.1038/s41591-019-0404-8. View

18.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

19.

Huang K, Park D, Ng S, Lee J, Ni X, Ng W . Selenium binding protein 1 in ovarian cancer. Int J Cancer. 2005; 118(10):2433-40. DOI: 10.1002/ijc.21671. View

20.

Zeng H, Zhao X, Tang C . Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling. Cancer Chemother Pharmacol. 2021; 88(2):223-233. DOI: 10.1007/s00280-021-04284-4. View